What is the recommendation regarding the use of neuroprotective agents for the treatment of patients with AIS?
At present, pharmacological or nonpharmacological treatments with putative neuroprotective actions are not recommended. This recommendation is unchanged from the 2013 AIS Guidelines and is classified as a Level III: No Benefit A Recommendation according to the ACC/AHA 2015 Recommendation Classification System.